ICCM — Icecure Medical Income Statement
0.000.00%
Last trade - 00:00
- $30.70m
- $20.24m
- $3.23m
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | USG | USG | USG | USG |
Status: | fx Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.61 | 3.87 | 4.14 | 3.08 | 3.23 |
Cost of Revenue | |||||
Gross Profit | 0.56 | 2.44 | 2.19 | 1.45 | 1.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 6.09 | 8.01 | 13.9 | 19.8 | 18.8 |
Operating Profit | -4.48 | -4.14 | -9.72 | -16.7 | -15.6 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4.64 | -3.73 | -9.89 | -17 | -14.7 |
Net Income After Taxes | -4.64 | -3.73 | -9.89 | -17 | -14.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.64 | -3.73 | -9.89 | -17 | -14.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.64 | -3.73 | -9.89 | -17 | -14.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.341 | -0.218 | -0.347 | -0.459 | -0.321 |
Dividends per Share |